Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambulatory glucose profile before and during pancreatic enzyme replacement therapy in diabetes with exocrine pancreatic insufficiency
2017-001227-45Phase 4Completed
- Sponsor
- Portsmouth Hospitals University NHS Trust
- Start
- May 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pancreatin in diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM) and exocrine pancreatic insufficiency (EPI), sponsored by Portsmouth Hospitals University NHS Trust. Primary endpoint: Mean interquartile range of glucose over 14 days at weeks 6–8 of PERT. Started May 2018; status: completed.
02
Drugs
pancreatin
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2017-001227-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001227-45.